2026-04-17T02:37:27Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2151852025-12-04T21:12:58Zcom_2072_1057col_2072_478781col_2072_478798col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Falo Zamora, Catalina author Azcarate, Juan author Fernández González, Sergi author Perez, Xavier author Petit, Anna author Perez Montero, Héctor author Vethencourt, Andrea author Vazquez, Silvia author Laplana, Maria author Ales, Miriam author Stradella, Agostina author Fullana, Bartomeu author Pla Farnós, Maria Jesús author Gumà i Garcia, Anna Maria author Ortega, Raul author Varela Rodríguez, Mar author Pérez, Diana author Ponton, Jose Luis author Cobo, Sara author Benítez, Ana author Campos, Miriam author Fernández, Adela author Villanueva, Rafael author Obadia, Verónica author Recalde, Sabela author Soler-Monsó, Teresa author López Ojeda, Anna author Martinez, Evelyn author Ponce i Sebastià, Jordi author Pernas, Sònia author Gil-Gil, Miguel author García Tejedor, María Amparo author 2024-09-16T17:12:08Z 2024-09-16T17:12:08Z 2024-06-30 2024-09-16T17:12:08Z Introduction: Neoadjuvant chemotherapy in breast cancer offers the possibility to facilitate breast and axillary surgery; it is a test of chemosensibility in vivo with significant prognostic value and may be used to tailor adjuvant treatment according to the response. Material and Methods: A retrospective single-institution cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHEr2 in Her2-positive cases, was studied. Survival was calculated at 5 and 10 years. Kaplan-Meier curves with a log-rank test were calculated for differences according to age, BRCA status, menopausal status, TNM, pathological and molecular surrogate subtype, 20% TIL cut-off, surgical procedure, response to chemotherapy and the presence of vascular invasion. Results: The pCR rate was 25.3% and was greater in HER2 (51.3%) and TNBC (31.7%) and in BRCA carriers (41.9%). The factors independently related to patient survival were pathology and molecular surrogate subtype, type of surgery, response to NACT and vascular invasion. BRCA status was a protective prognostic factor without reaching statistical significance, with an HR 0.5 (95%CI 0.1-1.4). Mastectomy presented a double risk of distant recurrence compared to breast-conservative surgery (BCS), supporting BCS as a safe option after NACT. After a mean follow-up of 126 (SD 43) months, luminal tumors presented a substantial difference in survival rates calculated at 5 or 10 years (81.2% compared to 74.7%), whereas that for TNBC was 75.3 and 73.5, respectively. The greatest difference was seen according to the response in patients with pCR, who exhibited a 10 years DDFS of 95.5% vs. 72.4% for those patients without pCR, p < 0001. This difference was especially meaningful in TNBC: the 10 years DDFS according to an RCB of 0 to 3 was 100%, 80.6%, 69% and 49.2%, respectively, p < 0001. Patients with a particularly poor prognosis were those with lobular carcinomas, with a 10 years DDFS of 42.9% vs. 79.7% for ductal carcinomas, p = 0.001, and patients with vascular invasion at the surgical specimen, with a 10 years DDFS of 59.2% vs. 83.6% for those patients without vascular invasion, p < 0.001. Remarkably, BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Conclusions: Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions. Càncer de mama Quimioteràpia Pronòstic mèdic Breast cancer Chemotherapy Prognosis Breast cancer patient’s outcomes after neoadjuvant chemotherapy and surgery at 5 and 10 years for stage II–III disease